FRESCO-2 Study Design Overview

Opinion
Video

Medical professionals provide background on the FRESCO-2 trial, which compared Fruquintinib to placebo in patients with heavily pretreated metastatic colorectal cancer. The trial enrolled patients who had exhausted all standard treatment options, including cytotoxic chemotherapy, targeted therapies, anti-VEGF agents, and BRAF inhibitors for those with BRAF mutations.

Related Videos
Video 7 - "Emerging Therapies for Refractory cGvHD: Potential Advantages of Axatilimab"
Video 6 - "Quality of Life + Clinical Monitoring Outside the Transplant Center"
Video 5 - "Second-Line Medications and Toxicities in GVHD"
Video 3 - "Adverse Event Profile and Tolerability of Fruquintinib Based on FRESCO-2 Trial"
Video 2 - "Overall Survival and Progression Free Survival in the FRESCO-2 Trial"
Video 5 - "Second-Line Treatment Considerations and Improving Outcomes in Breast Cancer"
Video 4 - "Impressions on Safety Data from EMERALD Subgroup Analysis"
Video 3 - "EMERALD: Elacestrant for ER+/HER2- Advanced Breast Cancer"
Video 2 - "Importance of Biomarker Testing in Breast Cancer"
Video 1 - "Patient Profile: A 49-Year-Old Woman with HR+/HER2- mBC and Liver and Lung Metastases"